COVID-19 treatment protocol in New Zealand

$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org April 2026 New Zealand Pakistan United Kingdom USA Russia Argentina Sudan Angola Colombia Kenya Mozambique Peru Philippines Spain Vietnam Brazil France Italy China Uzbekistan Iran Nepal Bangladesh Ethiopia Ghana Mexico South Korea Saudi Arabia Algeria Morocco Yemen Poland Venezuela India DR Congo Madagascar Thailand Uganda Egypt Nigeria Bolivia Taiwan Zambia Fiji Bosnia-Herzegovina Ukraine Côte d'Ivoire Greece Iceland Mongolia Czechia Israel Belarus North Macedonia Hong Kong Qatar Panama Serbia CAR New Zealand favored high-profit treatments.The average efficacy of treatments was moderate.High-cost protocols reduce early treatment, andforgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org April 2026 New Zealand Pakistan United Kingdom USA Russia Argentina Sudan Angola Colombia Kenya Mozambique Peru Philippines Spain Vietnam Brazil France Japan China Uzbekistan Iran Nepal Bangladesh Ethiopia Germany Saudi Arabia Algeria Morocco Yemen Poland Venezuela India DR Congo Madagascar Thailand Uganda Egypt Nigeria Bolivia Taiwan Zambia Fiji Bosnia-Herzegovina Ukraine Côte d'Ivoire Eritrea Bulgaria Greece Slovakia Singapore Iceland Mongolia Czechia Israel Belarus North Macedonia Hong Kong Qatar Panama Serbia CAR New Zealand favored high-profit treatments.The average efficacy was moderate.High-cost protocols reduce early treatment,and forgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
Countries adopted very different treatment protocols for COVID-19. Some countries preferred novel high-profit treatments, while others also used many low-cost treatments. Low-cost non-prescription treatments can greatly increase treatment—especially early treatment—due to lower barriers to access, and research shows complementary and synergistic benefits with many treatments1-17.
The plot shows the average efficacy and cost of approved treatments in each country. Actual usage varied significantly from official protocols in many regions. Top countries by population are shown where space precludes showing all country names.
(during pandemic, most mAbs are no longer recommended due to reduced efficacy with modern variants)
Submit updates or corrections.
References